PMID- 25676399
OWN - NLM
STAT- MEDLINE
DCOM- 20151105
LR  - 20191210
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 18
IP  - 2
DP  - 2015 Feb
TI  - [Assessment of ALK rearrangement in non-small cell lung cancer: using enhancing 
      immunohistochemical way and fluorescence in situ hybridization].
PG  - 75-9
LID - 10.3779/j.issn.1009-3419.2015.02.04 [doi]
AB  - BACKGROUND: Besides epidermal growth factor receptor (EGFR) mutation, the 
      non-small cell lung cancer (NSCLC) of anaplastic lymphoma kinase (ALK) 
      rearrangement becomes another important clinical subtype. A specific and 
      high-sensitive and economical detection way is convenience for identification of 
      ALK positive NSCLC quickly and accurately. So the objective of our research is to 
      detect ALK rearrangement in 172 cases of NSCLC by using enhancing 
      immunohistochemical way (ventana-IHC, V-IHC). METHODS: ALK rearrangement in 172 
      NSCLC samples was detected by using V-IHC, and positive staining cases were 
      further verified by fluorescence in situ hybridization (FISH). RESULTS: Among 172 
      NSCLC cases, there were 12 positive staining. The positive results were confirmed 
      by FISH and 11 cases were FISH positive. The overall concordance between V-IHC 
      and FISH is 91.7% (11/12). CONCLUSIONS: The V-IHC method is a reliable method for 
      ALK arrangement and could be used in clinical screen and diagnosis.
FAU - Meng, Hui
AU  - Meng H
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Gao, Xianzheng
AU  - Gao X
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Zhang, Lan
AU  - Zhang L
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Liu, Fang
AU  - Liu F
AD  - Pfizer Oncology Medical Affairs, Chengdu 610041, China.
FAU - Li, Wencai
AU  - Li W
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
LA  - chi
PT  - Evaluation Study
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Non-Small-Cell Lung/enzymology/*genetics
MH  - Female
MH  - *Gene Rearrangement
MH  - Humans
MH  - Immunochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Lung Neoplasms/enzymology/*genetics
MH  - Male
MH  - Middle Aged
MH  - Receptor Protein-Tyrosine Kinases/*genetics
PMC - PMC5999847
EDAT- 2015/02/14 06:00
MHDA- 2015/11/06 06:00
PMCR- 2015/02/20
CRDT- 2015/02/14 06:00
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2015/11/06 06:00 [medline]
PHST- 2015/02/20 00:00 [pmc-release]
AID - zgfazz-18-2-75 [pii]
AID - 10.3779/j.issn.1009-3419.2015.02.04 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):75-9. doi: 
      10.3779/j.issn.1009-3419.2015.02.04.